


A healthy liver brings harmony to your body



**A diseased liver
disrupts your
well-being**

LIFESOMIX

Peptide Power: Harmonizing Liver Disease

PROBLEM

MASLD (formerly NAFLD): the most prevalent chronic liver disease worldwide

Prevalence


~30% of adults today



Up to ~40-50% by 2030

Risk Factors:

Obesity
Type 2 Diabetes
Insulin Resistance



doi: 10.1016/j.jhep.2018.05.036

doi.org/10.3350/cmh.2022.0239

Urgent need for new therapies addressing fat accumulation, inflammation and fibrosis



SOLUTION

Drug option: SOCS1-mimetic peptide Strategy to control JAK/STAT overactivation

Dysregulation of the
JAK/STAT-SOCS axis
drives MASLD progression



SOCS1
regulatory
domain



SOCS1 PEPTIDOMIMETICS
Lead candidate & derivatives

Restoration of
signaling balance

Slowing MASLD progression

PROOF OF CONCEPT (I)

Strong in vivo efficacy in clinically relevant MASLD/MASH models

Dietary models
HFD, MCD





Obesity/type 2 diabetes



2-10 ug/g BW i.p. (3-12 weeks)

Biological effects:

- Rebalances disease-driving gene expression
- Reduces steatosis, inflammation, oxidative stress, and fibrosis
- Favorable safety profile



SOCS1 derived peptides for use in the treatment of liver diseases.

*Fundación Instituto de Investigación Sanitaria
Fundación Jiménez Díaz (IIS-FJD)*

Universidad Autónoma de Madrid (UAM)

Centro de Investigación Biomédica en Red (CIBER)

iis | INSTITUTO DE
FJD | INVESTIGACIÓN
SANITARIA
FUNDACIÓN JIMÉNEZ DÍAZ

UAM
Universidad Autónoma
de Madrid

ciber | DEM
CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED
Diabetes y Enfermedades Metabólicas Asociadas



Acknowledgement of receipt

We hereby acknowledge receipt of your request for grant of a European patent as follows:

Submission number	300465667
Application number	EP22383040.7
File No. to be used for priority declarations	EP22383040
Date of receipt	28 October 2022



PCT/EP2023/079934 (26.10.2023)

Favorable ISR (30.01.2024)

National Phase Entry: 28.04.2025

MARKET ANALYSIS

Growing Market, Limited Treatment Options



➤ Lifestyle modification is insufficient for advanced disease







➤ Off-label drugs show modest benefit

➤ One approved disease-specific therapy (Resmetirom), for non-cirrhotic MASH

Significant unmet need in a rapidly expanding therapeutic market

COMPETITORS & STRATEGIC POSITIONING

Compounds on Phase III trials for MASH

Molecule (Brand)	Mechanism of Action	Developer
UPSTREAM METABOLIC MODULATORS		
Semaglutide (Ozempic)	GLP-1R agonist	
Efruxifermin	Fc-FGF21 analog	
HEPATIC FAT ACCUMULATION INHIBITORS		
Resmetirom	THR-β agonist	
Lanifibranor	PPAR-α/γ/δ agonist	
Aramchol	SCD1 inhibitor	
ANTI-FIBROTICS		
Belapectin	Galectin-3 inhibitor	


FDA (Aug 2025)

FDA (Mar 2024)
EMA (Jun 2025)

*Non-cirrhotic
MASH with
moderate to
advanced liver
fibrosis*


Lifesomix approach

- Novel SOCS1-based therapeutic strategy.
- Broad multi-hit efficacy across steatosis, inflammation and fibrosis, with favorable cardiovascular safety.



**Potential anti-fibrotic activity
beyond MASLD**

DEVELOPMENT ROADMAP & PROJECTED FUNDING NEEDS



TEAM



Carmen Gómez-Guerrero, PhD
Professor of Medicine, UAM
Translational Researcher, IIS-FJD
Co-founder | CEO & CSO



Jesús Egido, MD PhD
Full Professor of Medicine, UAM
Clinical Investigator, IIS-FJD
Co-founder | CMO

ADVISORY BOARD

Gonzalo Hernández (MD, PhD) – ESAME Biomedical
Ibrahim Farr (MD, PhD), FFPM – Pivotal
Jorge Alemany (MD, PhD) – Biotech entrepreneur
Daniela Marasco (PhD) – University of Naples Federico II
José Tuñón (MD, PhD) – Fundación Jiménez Díaz / UAM
Hernán Quiceno (MD, MSc) – Fundación Jiménez Díaz
Ángela M. Valverde (PhD) – IIBm, CSIC-UAM, CIBERDEM
Antonio Zorzano (PhD) – IRB, University of Barcelona
Francisco J. Otero (PhD) – University Santiago de Compostela


Renal, Vascular and Diabetes Reseach Lab (IIS-FJD/UAM)



Sebastián Mas - Senior Scientist
María Kavanagh - PhD researcher
Isabel Herrero - PhD researcher
Raquel Alvarez - Research technician

STATUS SUMMARY

Strategic Position

- UAM-accredited spin-off incorporated Dec 2025
- Located at Madrid Science Park  FUNDACIÓN Parque Científico de Madrid
- Patent in national phase (US, EU, JP, BR)
- Development roadmap validated by biotech advisors

Scientific Execution

- Lead candidate selected
- Advanced preclinical validation ongoing
- CMC and regulatory strategy in preparation

Funding and Ecosystem

- ~€450k non-dilutive public funding secured for the preclinical development program
- Institutional support: UAM Emprende, S4i, DeepTech Madri+d
- Discussions with a MASH-focused CRO and translational partners

Team Expansion

- COO recruitment in progress



www.lifesomix.com

contact@lifesomix.com